Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Omnicell (NASDAQ: OMCL) and its peers.

The healthcare technology sector provides software and data analytics to help hospitals and clinics streamline operations and improve patient outcomes, often through value-based care models. Future growth is expected as providers prioritize digital transformation to manage rising costs and patient demands. Tailwinds include the adoption of AI-driven tools and government incentives for digitization. There challenges as well, including long sales cycles and slow adoption by providers, who may be resistance to change. Tightening hospital budgets and cybersecurity threats are additional risks that could slow adoption.

The 4 healthcare technology for providers stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 1.8% while next quarter’s revenue guidance was in line.

Luckily, healthcare technology for providers stocks have performed well with share prices up 10.1% on average since the latest earnings results.

Weakest Q4: Omnicell (NASDAQ: OMCL)

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ: OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Omnicell reported revenues of $314 million, up 2.3% year on year. This print was in line with analysts’ expectations, but overall, it was a mixed quarter for the company with EBITDA guidance for next quarter exceeding analysts’ expectations but a significant miss of analysts’ full-year EPS guidance estimates.

“We finished 2025 with solid fourth quarter financial results, delivering full year 2025 total revenues, product bookings and annual recurring revenues (‘ARR’) all above the mid-point of our previously issued guidance ranges,” stated Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell.

Omnicell delivered the weakest performance against analyst estimates of the whole group. The stock is down 19.6% since reporting and currently trades at $37.54.

Is now the time to buy Omnicell? Access our full analysis of the earnings results here, it’s free.

Best Q4: Privia Health (NASDAQ: PRVA)

Operating in 13 states and the District of Columbia with over 4,300 providers serving more than 4.8 million patients, Privia Health (NASDAQ: PRVA) is a technology-driven company that helps physicians optimize their practices, improve patient experiences, and transition to value-based care models.

Privia Health reported revenues of $541.2 million, up 17.4% year on year, outperforming analysts’ expectations by 4.8%. The business had a stunning quarter with a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

Privia Health delivered the biggest analyst estimates beat and highest full-year guidance raise among its peers. The market seems content with the results as the stock is up 3.5% since reporting. It currently trades at $23.45.

Is now the time to buy Privia Health? Access our full analysis of the earnings results here, it’s free.

Astrana Health (NASDAQ: ASTH)

Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ: ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.

Astrana Health reported revenues of $950.5 million, up 42.9% year on year, exceeding analysts’ expectations by 2.3%. It may have had the worst quarter among its peers, but its results were still good as it also locked in a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.

Astrana Health delivered the fastest revenue growth but had the weakest full-year guidance update in the group. Interestingly, the stock is up 43.8% since the results and currently trades at $29.24.

Read our full analysis of Astrana Health’s results here.

Evolent Health (NYSE: EVH)

Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE: EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.

Evolent Health reported revenues of $468.7 million, down 27.5% year on year. This print was in line with analysts’ expectations. Overall, it was a strong quarter as it also logged a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

Evolent Health had the slowest revenue growth among its peers. The stock is up 12.7% since reporting and currently trades at $2.88.

Read our full, actionable report on Evolent Health here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.